Details for Patent: 8,501,712

Which drugs does patent 8,501,712 protect, and when does it expire?

Patent 8,501,712 protects EUCRISA and is included in one NDA.

Protection for EUCRISA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-two patent family members in twenty-four countries.

Summary for Patent: 8,501,712

Title:	Boron-containing small molecules as anti-inflammatory agents
Abstract:	Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.
Inventor(s):	Stephen J. Baker, Virginia Sanders, Tsutomu Akama, Carolyn Bellinger-Kawahara, Yvonne Freund, Kirk R. Maples, Jacob J. Plattner, Yong-Kang Zhang, Huchen Zhou, Vincent S. Hernandez
Assignee:	Anacor Pharmaceuticals LLC
Application Number:	US13/453,682
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,501,712
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Device;

Drugs Protected by US Patent 8,501,712

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Anacor Pharms Inc	EUCRISA	crisaborole	OINTMENT;TOPICAL	207695-001	Dec 14, 2016		RX	Yes	Yes					Y

International Family Members for US Patent 8,501,712

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007214421
Brazil	PI0708051
Canada	2642583